Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

References

• Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–1769. doi:10.1016/S0140-6736(20)32381-3
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet. 2017;389(10087):2430–2442. doi:10.1016/S0140-6736(16)32454-0
   PubMed Web of Science ®Google Scholar
• Li Y, Tsang JY, Tam F, Loong T, Tse GM. Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment. EBioMedicine. 2023;91:104571. doi:10.1016/j.ebiom.2023.104571
   PubMed Web of Science ®Google Scholar
• Popović M, Silovski T, Križić M, Dedić Plavetić N. HER2 low breast cancer: a new subtype or a trojan for cytotoxic drug delivery? Int J Mol Sci. 2023;24(9):8206. doi:10.3390/IJMS24098206
   PubMed Web of Science ®Google Scholar
• Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. doi:10.1038/s41523-022-00468-0
   PubMed Web of Science ®Google Scholar
• Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F. Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives. Front Oncol. 2021;11:769280. doi:10.3389/fonc.2021.769280
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0
   PubMed Web of Science ®Google Scholar
• Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417. doi:10.3389/fmolb.2022.836417
   PubMed Web of Science ®Google Scholar
• Park SY, Choi JH, Nam JS. Targeting cancer stem cells in triple-negative breast cancer. Cancers. 2019;11(7):965. doi:10.3390/cancers11070965
   PubMed Web of Science ®Google Scholar
• Kumar H, Gupta NV, Jain R, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res. 2023. doi:10.1016/j.jare.2023.02.005
   Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/jci45014
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC). J Clin Med. 2023;12(4):1524. doi:10.3390/JCM12041524
   PubMed Web of Science ®Google Scholar
• Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2016;34(20):2416–2427. doi:10.1200/JCO.2016.67.0182
   PubMed Web of Science ®Google Scholar
• Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance. Biomedicines. 2021;9(11):1512. doi:10.3390/biomedicines9111512
   PubMed Web of Science ®Google Scholar
• Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022;8(1):47. doi:10.1038/s41523-022-00411-3
   PubMedGoogle Scholar
• Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022;8(1):23. doi:10.1038/s41523-022-00386-1
   PubMed Web of Science ®Google Scholar
• Jeong JH, Kim SB. Antibody-drug conjugates targeting Trop-2: clinical developments in early breast cancer therapy. Breast. 2022;66:199–203. doi:10.1016/j.breast.2022.10.015
   PubMed Web of Science ®Google Scholar
• Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609–1623.
   PubMed Web of Science ®Google Scholar
• You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating therapeutic effects of epidermal growth factor receptor inhibition in triple-negative breast cancer. Pharmaceuticals. 2021;14(6):589. doi:10.3390/ph14060589
   Web of Science ®Google Scholar
• Maennling AE, Tur MK, Niebert M, et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers. 2019;11(12):1826. doi:10.3390/cancers11121826
   PubMed Web of Science ®Google Scholar
• Chan-Penebre E, Kuplast KG, Majer CR, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11(6):432–437. doi:10.1038/nchembio.1810
   PubMed Web of Science ®Google Scholar
• Vinet M, Suresh S, Maire V, et al. Protein arginine methyltransferase 5: a novel therapeutic target for triple-negative breast cancers. Cancer Med. 2019;8(5):2414–2428. doi:10.1002/cam4.2114
   PubMed Web of Science ®Google Scholar
• Larsen SC, Sylvestersen KB, Mund A, et al. Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci Signal. 2016;9(443):rs9. doi:10.1126/scisignal.aaf7329
   PubMed Web of Science ®Google Scholar
• Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65(1):8–24. doi:10.1016/j.molcel.2016.11.003
   PubMed Web of Science ®Google Scholar
• Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret? Trends Mol Med. 2019;25(11):993–1009. doi:10.1016/j.molmed.2019.05.007
   PubMed Web of Science ®Google Scholar
• Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20(7):509–530. doi:10.1038/s41573-021-00159-8
   PubMed Web of Science ®Google Scholar
• Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13(1):37–50. doi:10.1038/nrc3409
   PubMed Web of Science ®Google Scholar
• Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20(10):642–657. doi:10.1038/s41580-019-0155-x
   PubMed Web of Science ®Google Scholar
• Guccione E, Schwarz M, Di Tullio F, Mzoughi S. Cancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors. Curr Opin Pharmacol. 2021;59:33–42. doi:10.1016/j.coph.2021.04.004
   PubMed Web of Science ®Google Scholar
• Suresh S, Huard S, Dubois T. CARM1/PRMT4: making its mark beyond its function as a transcriptional coactivator. Trends Cell Biol. 2021;31(5):402–417. doi:10.1016/j.tcb.2020.12.010
   PubMed Web of Science ®Google Scholar
• Suresh S, Huard S, Brisson A, et al. PRMT1 regulates EGFR and wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer. Cancers. 2022;14(2):306. doi:10.3390/cancers14020306
   PubMed Web of Science ®Google Scholar
• Wu Q, Nie DY, Ba-alawi W, et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat Chem Biol. 2022;18(8):821–830. doi:10.1038/s41589-022-01024-4
   PubMed Web of Science ®Google Scholar
• Suresh S, Vinet M, Dakroub R, et al. Expression, localization and prognosis association of MEP50 in breast cancer. Cancers. 2022;14(19):4766. doi:10.3390/cancers14194766
   PubMed Web of Science ®Google Scholar
• Zhou Z, Feng Z, Hu D, et al. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. EBioMedicine. 2019;44:98–111. doi:10.1016/j.ebiom.2019.05.011
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang Z, Zhang J, Ling R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol. 2017;39(4):1010428317695917. doi:10.1177/1010428317695917
   Google Scholar
• Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2022;5(3):58–67. doi:10.36401/jipo-22-1
   PubMedGoogle Scholar
• Wang X, Qiu T, Wu Y, et al. Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer. Cell Death Differ. 2021;28(10):2931–2945. doi:10.1038/s41418-021-00793-0
   PubMed Web of Science ®Google Scholar
• Gerhart SV, Kellner WA, Thompson C, et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep. 2018;8(1):9711. doi:10.1038/s41598-018-28002-y
   PubMed Web of Science ®Google Scholar
• Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother. 2006;7(2):177–193. doi:10.1517/14656566.7.2.177
   PubMed Web of Science ®Google Scholar
• Minna JD, Dowell J. Erlotinib hydrochloride. Nat Rev Drug Discov. 2005;Suppl:S14–5. doi:10.1038/nrd1612
   PubMedGoogle Scholar
• Collins DM, Conlon NT, Kannan S, et al. Preclinical characteristics of the irreversible Pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-Positive and HER2-mutated breast cancer. Cancers. 2019;11(6):737. doi:10.3390/cancers11060737
   PubMed Web of Science ®Google Scholar
• Conlon NT, Kooijman JJ, van Gerwen SJC, et al. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. Br J Cancer. 2021;124(7):1249–1259. doi:10.1038/s41416-020-01257-x
   PubMed Web of Science ®Google Scholar
• Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32(18):2866–2868. doi:10.1093/bioinformatics/btw230
   PubMed Web of Science ®Google Scholar
• Zhao L, Au JLS, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci. 2010;2(1):241. doi:10.2741/E86
   Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. doi:10.1038/nmeth.2089
   PubMed Web of Science ®Google Scholar
• Maire V, Mahmood F, Rigaill G, et al. LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors. Cancer Med. 2019;8(1):325. doi:10.1002/CAM4.1923
   PubMed Web of Science ®Google Scholar
• Lerebours F, Vacher S, Guinebretiere JM, et al. Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer? J Adv Res. 2021;28:77. doi:10.1016/J.JARE.2020.08.009
   PubMed Web of Science ®Google Scholar
• Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselkä agreement revisited. Front Pharmacol. 2015;6:181. doi:10.3389/fphar.2015.00181
   PubMed Web of Science ®Google Scholar
• Meyer CT, Wooten DJ, Lopez CF, Quaranta V. Charting the fragmented landscape of drug synergy. Trends Pharmacol Sci. 2020;41(4):266–280. doi:10.1016/j.tips.2020.01.011
   PubMed Web of Science ®Google Scholar
• Smith SE, Mellor P, Ward AK, et al. Molecular characterization of breast cancer cell lines through multiple omic approaches. Br Cancer Res. 2017;19(1):1–12. doi:10.1186/S13058-017-0855-0/FIGURES/5
   PubMedGoogle Scholar
• Yin S, Liu L, Brobbey C, et al. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Nat Commun. 2021;12(1):3444. doi:10.1038/s41467-021-23833-2
   PubMed Web of Science ®Google Scholar
• Brobbey C, Yin S, Liu L, et al. Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer. Sci Rep. 2023;13(1):1–13. doi:10.1038/s41598-023-37706-9
   PubMed Web of Science ®Google Scholar
• Mueller HS, Fowler CE, Dalin S, et al. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. Proc Natl Acad Sci U S A. 2021;118(34). doi:10.1073/pnas.2024055118
   Web of Science ®Google Scholar
• Musiani D, Giambruno R, Massignani E, et al. PRMT1 is recruited via DNA-PK to chromatin where it sustains the senescence-associated secretory phenotype in response to cisplatin. Cell Rep. 2020;30(4):1208–1222.e9. doi:10.1016/j.celrep.2019.12.061
   PubMed Web of Science ®Google Scholar
• Epstein DM, Buck E. Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function. J Clin Invest. 2015;125(12):4320–4322. doi:10.1172/jci85001
   PubMed Web of Science ®Google Scholar
• Liao HW, Hsu JM, Xia W, et al. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015;125(12):4529–4543. doi:10.1172/jci82826
   PubMed Web of Science ®Google Scholar
• Nakai K, Xia W, Liao HW, Saito M, Hung MC, Yamaguchi H. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018;25(1):74–80. doi:10.1007/s12282-017-0790-z
   PubMed Web of Science ®Google Scholar
• Wang WJ, Hsu JM, Wang YN, et al. An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. Am J Cancer Res. 2019;9(1):180–185.
   PubMed Web of Science ®Google Scholar
• Hsu JM, Chen CT, Chou CK, et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol. 2011;13(2):174–181. doi:10.1038/ncb2158
   PubMed Web of Science ®Google Scholar
• Yao B, Gui T, Zeng X, et al. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Med. 2021;13(1):58. doi:10.1186/s13073-021-00871-5
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang XO, Rozen EJ, et al. PRMT5 activates AKT via methylation to promote tumor metastasis. Nat Commun. 2022;13(1):3955. doi:10.1038/s41467-022-31645-1
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England J Med. 2022;387(1):9–20. doi:10.1056/NEJMOA2203690/SUPPL_FILE/NEJMOA2203690_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first targeted therapy for HER2-Low breast cancer. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer. Accessed May 30, 2023.
   Google Scholar
• Hu R, Zhou B, Chen Z, et al. PRMT5 inhibition promotes PD-L1 expression and immuno-resistance in lung cancer. Front Immunol. 2021;12:722188. doi:10.3389/fimmu.2021.722188
   PubMed Web of Science ®Google Scholar
• Che Y, Liu Y, Yao Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023;13(1):27. doi:10.1038/s41408-023-00799-6
   PubMed Web of Science ®Google Scholar
• AbuHammad S, Cullinane C, Martin C, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci U S A. 2019;116(36):17990–18000. doi:10.1073/pnas.1901323116
   PubMed Web of Science ®Google Scholar
• Yang L, Ma DW, Cao YP, et al. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression. Theranostics. 2021;11(8):3742–3759. doi:10.7150/thno.53023
   PubMed Web of Science ®Google Scholar
• Fedoriw A, Rajapurkar SR, O’Brien S, et al. Anti-tumor activity of the type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019;36(1):100–114.e25. doi:10.1016/j.ccell.2019.05.014
   PubMed Web of Science ®Google Scholar
• Fong JY, Pignata L, Goy PA, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36(2):194–209.e9. doi:10.1016/j.ccell.2019.07.003
   PubMed Web of Science ®Google Scholar
• Holmes B, Benavides-Serrato A, Saunders JT, et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neurooncol. 2019;145(1):11–22. doi:10.1007/s11060-019-03274-0
   PubMed Web of Science ®Google Scholar
• Hong E, Barczak W, Park S, et al. Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. Cell Death Dis. 2023;14(2):93. doi:10.1038/s41419-023-05630-5
   PubMed Web of Science ®Google Scholar
• O’Brien S, Butticello M, Thompson C, et al. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer. 2023;23(1):775. doi:10.1186/S12885-023-11260-Z
   PubMed Web of Science ®Google Scholar
• Wei X, Yang J, Adair SJ, et al. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Sci U S A. 2020;117(45):28068–28079. doi:10.1073/pnas.2009899117
   PubMed Web of Science ®Google Scholar